· b. nitrosoureas-agente alquilante c. fluorouracilo-antimetabolito d. irinotecan-lnhibidor de...

5

Upload: vanthien

Post on 20-Sep-2018

213 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: · b. Nitrosoureas-agente alquilante c. Fluorouracilo-antimetabolito d. Irinotecan-lnhibidor de Topoisomerasa I ... EXAMEN FARMA MOD. 3 Y 4 11 de ENERO de 2007 APELLIDOS Y NOMBRE:

Page 2: · b. Nitrosoureas-agente alquilante c. Fluorouracilo-antimetabolito d. Irinotecan-lnhibidor de Topoisomerasa I ... EXAMEN FARMA MOD. 3 Y 4 11 de ENERO de 2007 APELLIDOS Y NOMBRE:

Page 3: · b. Nitrosoureas-agente alquilante c. Fluorouracilo-antimetabolito d. Irinotecan-lnhibidor de Topoisomerasa I ... EXAMEN FARMA MOD. 3 Y 4 11 de ENERO de 2007 APELLIDOS Y NOMBRE:

Page 4: · b. Nitrosoureas-agente alquilante c. Fluorouracilo-antimetabolito d. Irinotecan-lnhibidor de Topoisomerasa I ... EXAMEN FARMA MOD. 3 Y 4 11 de ENERO de 2007 APELLIDOS Y NOMBRE:

Page 5: · b. Nitrosoureas-agente alquilante c. Fluorouracilo-antimetabolito d. Irinotecan-lnhibidor de Topoisomerasa I ... EXAMEN FARMA MOD. 3 Y 4 11 de ENERO de 2007 APELLIDOS Y NOMBRE:

ACNS0821 Temozolomide with Irinotecan versus Temozolomide ... · temozolomide, irinotecan and bevacizumab for recurrent medulloblastoma (MB)/PNET of childhood. Measurable disease

Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon … · Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma Salome Paillas1,

Development and Targeting Efficiency of Irinotecan

PROPOSITO EVALUAR PANITUMUMAB MAS FLUOROURACILO, LEUCOVORINA Y OXALIPLATINO (MFOLFOX6) O BEVACIZUMAB MAS MFOLFOX6, EN PACIENTES CON CANCER COLORRECTAL

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...Liposomal irinotecan (MM-398, PEP02) Liposomal irinotecan (nal-IRI): novel formulation developed

Evaluation of Eribulin Combined with Irinotecan for Treatment of … · Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. ... part this

Tratamento cirúrgico e médico (5-fluorouracilo) de um ...mendada a crioterapia ou a aplicação intralesional de fármacos quimioterápicos, como o 5-fluorouracilo ou a cisplatina

Parenteral Drug Delivery Market Trends...(irinotecan hydrochloride) Formulation may realize promise of liposomes and irinotecan in a challenging indication. Notable Approvals: 2015

Targeting the p38 MAPK Pathway Inhibits Irinotecan ...cancerres.aacrjournals.org/content/canres/early/2011/01/21/0008-5472... · Targeting the p38 MAPK Pathway Inhibits Irinotecan

Irinotecan-platinum combination therapy for previously untreated … · 2018. 8. 10. · 2008 Norway and Sweden 209 IC: irinotecan 175 mg/m2 d1 carboplatin AUC 4 mg.min/ml d1(105)

Photodynamic Therapy Synergizes with Irinotecan to ...cancerres.aacrjournals.org/content/canres/76/5/1066.full.pdf · Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory

Presentación de PowerPoints076f68c3bf6790f7.jimcontent.com/download/version... · a inhibición de la síntesis de ADN por quinolonas exige la topoisomerasa objetivo de tener la

Preclinical)evalua,on)and)biomarker…€¦ · CT3$LDA$Tumor$Volume$/$10$Cells PBS Irinotecan a/LGR5$ a/LGR5$Irinotecan 0 50 100 150 200 250 300 Prior$Treatment$Group m ³ 1 Preclinical)evalua,on)and)biomarker

Gene Expression Profiling of the Irinotecan Pathway in ... · pathway using gene expression data for 24 irinotecan pathway genes in human colorectal neoplastic and normal tissues

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), …clincancerres.aacrjournals.org/content/clincanres/21/5/...Cancer Therapy: Preclinical Activity of MM-398, Nanoliposomal Irinotecan

Irinotecan pharmacokinetic and pharmacogenomic alterations ... · Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck

2015 Advances in Colorectal Cancer Irinotecan, a key ... · of metastatic colorectal cancer (CRC) at the end of the last century, survival has improved dramatically. Irinotecan is

Preclinical Activity of Nanoliposomal Irinotecan Is ... · Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion Ashish

Pegylated liposomal irinotecan hydrochloride trihydrate ...livrepository.liverpool.ac.uk/...iri_PE_manuscript_re-submit… · Web viewThe National Institute for Health and Care

תוחקורויבו הקיטניקוקמרפ - BGU...BCRP-mitoxantrone, topotecan, irinotecan, methotrexate, doxorubicin MRP1 -vinblastine, etoposide, methotrexate, cisplatin :תודימעה

MA En fase II-undersøgelse af irinotecan ugentligt til patienter … Filer/NEGIRI_version_16-05-2013... · 2020. 1. 17. · MA En fase II-undersøgelse af irinotecan ugentligt til

DC beads loaded with Irinotecan : precilinical in-vitro & in-vivo evaluation

Efficacy of FOLFIRI-3 or other irinotecan-based regimens

5.09IRINOTECAN,43 mg irinotecan (nanoliposomal) …€¦ · Web viewThe submission requested a Section 100 (Efficient Funding of Chemotherapy) Authority Required listing for irinotecan

A 3 Gene Signature for Irinotecan

DETERMINACIÓN DE CONCORDANCIA DE EXPRESIVIDAD … · 2 entre inmunohistoquÍmica e hibridaciÓn in situ fluorescente (fish) y su relaciÓn con expresiÓn de topoisomerasa a2 en carcinoma

Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan versus Cetuximab/Bevacizumab in Irinotecan-Refractory Colorectal Cancer LB Saltz, HJ Lenz,

Irinotecan - Topoisomerase Poison

EFECTOS DE LA COMBINACIÓN DE 5-FLUOROURACILO Y …

artíCulo original Dermatología489 Dermatol Rev Mex 2014;58:489-500. artíCulo original Estudio comparativo entre 5-fluorouracilo liposomal a 0.5% en crema y 5-fluorouracilo a 5%

ANEXO I RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO · Cancro gástrico metastizado KANJINTI, em associação com capecitabina ou 5-fluorouracilo, e cisplatina, está indicado no tratamento

PRODUCT MONOGRAPH IRINOTECAN HYDROCHLORIDE …

Randomized Phase III Trial of Cetuximab Plus Irinotecan vs Irinotecan Alone for Metastatic Colorectal Cancer (mCRC) after Failing Prior Oxaliplatin-based

Gene Expression Profiling of the Irinotecan Pathway in ...clincancerres.aacrjournals.org/content/clincanres/11/5/2053.full.pdf · Gene Expression Profiling of the Irinotecan Pathway